Screening Tests and Support in Positive Human Papilloma Virus Tests

Abstract

Screening for the detection of Cervical Cancer (CC) is moving from cytology or Papanicolaou (Pap) test to the detection of the primary highrisk Human Papillomavirus (HPV) test, based on evidence for this change, with support or triage options for positive HPV test results with better access innovations. The test of higher specificity such as cytology makes it an option for triage in positive HPV tests; but cytology and genotyping have been recommended for all positive HPV tests, especially for the other pool-positive hr-HPVs; but HPV-16/18 negative. Screening with primary HPV testing has been shown to be effective, affordable, and acceptable to women, especially in emerging countries; the use of Dual Staining (DS) to classify positive HPV results has higher sensitivity and specificity than HPV-16/18 genotyping or cytology at triage.